IMTherapeutics
Woburn
About IMTherapeutics
IM Therapeutics develops personalized immunotherapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen (HLA) genes. Their lead candidate drug is an oral drug that starves the autoimmune process in type 1 diabetes (T1D) by blocking DQ8 on specific immune cells. Their goal is to preserve pancreatic beta-cell function and maintain normal insulin production in at-risk and early-stage patients with type 1 diabetes. They are leveraging Their HLA platform to expand their pipeline beyond T1D, to include drug development for Celiac disease (gluten sensitivity) as well as potential additional autoimmune diseases. It was founded in 2015 and is headquartered in Aurora, Colorado.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2019)
- Website: imtherapeutics.com
- Phone: 303-544-2104
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/imtherapeutics-127611 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.